Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

Risk of Morning Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02242331

Enrollment

19805

Registered

2014-09-17

Start date

2001-06-30

Completion date

Unknown

Last updated

2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

This post-marketing surveillance study is designed to supplement under conditions of normal clinical practice data on safety, tolerability and efficacy of Micardis® collected in clinical studies with special emphasis on the control of blood pressure in the morning before intake of the next antihypertensive drug

Interventions

DRUGMicardis®

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Essential hypertension * At least 18 years of age

Exclusion criteria

* NA

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline in blood pressure	Baseline, after 3 months	with special emphasis on the morning blood pressure, before intake of the next antihypertensive treatment
Number of patients with adverse events	up to 3 months	—
Changes from baseline in pulse rate	Baseline, after 3 months	—

Secondary

Measure	Time frame
Assessment of efficacy by investigator on 5- point scale	after 3 months
Assessment of tolerability by investigator on a 5-point scale	after 3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026